Independent University of Lille Study Shows Rose Bengal Sodium Produces Opposing Mechanistic Effects at the Same Dose
A peer-reviewed study by OncoThAI at the University of Lille, published in Molecular Therapy: Oncology, validates Provectus’s lead asset PV-10. The independent research demonstrates that Rose Bengal Sodium (RBS) produces opposing immune effects at the same dose: stimulating anti-tumor immunity in melanoma cells while suppressing peripheral immune cells.
Key figures
- Drug Name
- PV-10
- Hbl dose low
- 32 µM
- Lnd dose low
- 74 µM
- Hbl dose high
- 492 µM
- Lnd dose high
- 1,043 µM
- Pdt efficacy hbl
- 121x more effective than RBS alone
- Pdt efficacy lnd
- 40x more effective than RBS alone
- Dose reduction hbl
- 15-fold
- Dose reduction lnd
- 14-fold
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.